Abiopharma

Sigyn Therapeutics is a development-stage company advancing next-generation medical devices to address life-threatening conditions with no FDA-approved treatments. Sigyn TherapyTM is a first-in-class device to address severe inflammatory disorders. It has been demonstrated to reduce the presence of bacterial toxins (including endotoxin), inflammatory cytokines, hepatic toxins, and infectious viral pathogens from human blood plasma. Based on these capabilities, Sigyn TherapyTM is a candidate to treat sepsis, the leading cause of death in U.S. hospitals and a $62 billion annual healthcare burden. The Company is also advancing Sigyn TherapyTM to treat endotoxemia and concurrent inflammation, which shorten the lives of dialysis patients. The Company is preparing to submit an Investigational Device Exemption (IDE) to FDA to support a feasibility study whose target enrollment is 12–15 ESRD patients. The study will integrate Sigyn Therapy™ in series with regularly scheduled dialysis treatments to evaluate safety and monitor changes in endotoxin and inflammatory cytokine levels during treatment. The Company is also developing novel devices to improve the targeted delivery of chemotherapy (ChemoPrepTM) and immunotherapeutic antibodies (ImmunePrepTM) to treat cancer. The advancement of these candidates is anticipated to occur through joint development relationships.

Additional info from OTC:
Sigyn Therapeutics is a development-stage company advancing next-generation medical devices to address life-threatening conditions with no FDA-approved treatments. Sigyn TherapyTM is a first-in-class device to address severe inflammatory disorders. It has been demonstrated to reduce the presence of bacterial toxins (including endotoxin), inflammatory cytokines, hepatic toxins, and infectious viral pathogens from human blood plasma. Based on these capabilities, Sigyn TherapyTM is a candidate to treat sepsis, the leading cause of death in U.S. hospitals and a $62 billion annual healthcare burden. The Company is also advancing Sigyn TherapyTM to treat endotoxemia and concurrent inflammation, which shorten the lives of dialysis patients. The Company is preparing to submit an Investigational Device Exemption (IDE) to FDA to support a feasibility study whose target enrollment is 12–15 ESRD patients. The study will integrate Sigyn Therapy™ in series with regularly scheduled dialysis treatments to evaluate safety and monitor changes in endotoxin and inflammatory cytokine levels during treatment. The Company is also developing novel devices to improve the targeted delivery of chemotherapy (ChemoPrepTM) and immunotherapeutic antibodies (ImmunePrepTM) to treat cancer. The advancement of these candidates is anticipated to occur through joint development relationships.